Last reviewed 2026-04-20 · How we verify

Patanol

At a glance

Approved indications

• Allergic conjunctivitis
• Allergic rhinitis
• Seasonal allergic rhinitis

Common side effects

• Headaches
• Asthenia
• Blurred vision
• Burning or stinging
• Cold syndrome
• Dry eye
• Foreign body sensation
• Hyperemia
• Hypersensitivity
• Keratitis
• Lid edema
• Nausea

Key clinical trials

• Azelastine Allergen Chamber - Onset of Action Study (PHASE2)
• Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis (PHASE2)
• Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment (PHASE4)
• Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis (PHASE4)
• Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis (PHASE2)
• A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis (PHASE4)
• A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis (PHASE4)
• Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Patanol CI brief — competitive landscape report
• Patanol updates RSS · CI watch RSS
• ORA, Inc. portfolio CI